We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Hydrogen Sulfide Detoxification and Butyrate Metabolism in Ulcerative Colitis

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: January 25, 2011
Last Update Posted: January 26, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Katholieke Universiteit Leuven
The purpose of this study is to evaluate the relation between sulphide detoxification and butyrate metabolism at the level of gene expression and enzyme activity in ulcerative colitis patients and healthy controls.

Ulcerative Colitis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Impact of the Mucosal Detoxification Mechanism of Hydrogen Sulphide on the Oxidation Pathway of Butyrate in Ulcerative Colitis

Resource links provided by NLM:

Further study details as provided by Katholieke Universiteit Leuven:

Biospecimen Retention:   Samples With DNA
colon tissue

Enrollment: 106
Study Start Date: October 2008
Study Completion Date: December 2010
Healthy controls
Ulcerative colitis


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
IBD patients clinic (Universitaire Ziekenhuizen Leuven)

Inclusion Criteria:

- Ulcerative colitis patients: patients diagnosed with ulcerative colitis

Exclusion Criteria:

  • Healthy controls: no diagnosis of inflammatory bowel diseases
  • Intake of antibiotics in the last month before the study
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01282905

Leuven, Belgium
Sponsors and Collaborators
Katholieke Universiteit Leuven
Principal Investigator: Kristin Verbeke, PhD Katholieke Universiteit Leuven
  More Information

Responsible Party: Prof. Kristin Verbeke, KULeuven
ClinicalTrials.gov Identifier: NCT01282905     History of Changes
Other Study ID Numbers: ML3999
First Submitted: January 24, 2011
First Posted: January 25, 2011
Last Update Posted: January 26, 2011
Last Verified: January 2011

Additional relevant MeSH terms:
Colitis, Ulcerative
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases
Hydrogen Sulfide
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs